Rithwick Rajagopal

Dr. Rithwick Rajagopal

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2020 in Ophthalmology Retina
Verified
Journal Article
Closed access
JLJames Liu
James Liu
EGElla Gibson
Ella Gibson
SRShawn Ramchal
Shawn Ramchal
VSVikram Shankar
Vikram Shankar
KPKisha Piggott
Kisha Piggott
RRRithwick Rajagopal
Rithwick Rajagopal

10 September 2019 in Current Diabetes Reports
Verified
Journal Article
Closed access
PDF file
AHAvinash Honasoge
Avinash Honasoge
ENEric Nudleman
Eric Nudleman
MSMorton Smith
Morton Smith
RRRithwick Rajagopal
Rithwick Rajagopal

1 November 2019 in Investigative Ophthalmology & Visual Science
Verified
Journal Article
Open access
PDF file
YBYicheng K. Bao
Yicheng K. Bao
YYYan Yan
Yan Yan
MGMae Gordon
Mae Gordon
JMJanet B. McGill
Janet B. McGill
MKMichael Kass
Michael Kass
RRRithwick Rajagopal
Rithwick Rajagopal
Purpose: Neuroretinopathy is increasingly being recognized as an independent cause of vision loss in diabetes. Visual field loss, as detected by frequency doubling technology (FDT)-based visual perimetry, is a sign of neuroretinopathy and occurs in early stages of diabetic retinopathy (DR). Here, we hypothesized that FDT visual field testing could identify patients with diabetic neuroretinopathy in the absence of clinically detectable microvascular DR. Methods: All National Health and Nutrition Examination Survey (NHANES) 2005–2008 participants receiving fundus photography and visual field screening by FDT were included in this study. Participants with self-reported glaucoma, use of glaucoma medications, or determination of glaucoma based on disk features were excluded. Visual fields were screened using FDT protocol in which participants underwent a 19-subfield suprathreshold test. Results: Patients with diabetes but no DR were more likely to have ≥1 subfield defects at 5%, 2%, and 1% probability levels than patients without diabetes (41.3% vs. 28.6%; 27.4% vs. 17.5%; 15.9% vs. 9.4%; all P < 0.0008). Multivariable regression showed that each additional glycated hemoglobin % (HbA1c) was associated with 19% greater odds of having ≥1 visual subfield defects in those with diabetes without DR (odds ratio: 1.19, 95% confidence interval: 1.07–1.33; P = 0.0020). Conclusions: Patients with diabetes have visual field defects in the absence of clinically detectable DR, suggesting neuroretinopathy precedes classical microvascular disease. These defects become more frequent with the onset of visible retinopathy and worsen as the retinopathy becomes more severe. Longitudinal studies are required to understand the pathogenesis of diabetic neuroretinopathy in relation to classic DR.

1 March 2016 in Survey of Ophthalmology
Verified
Journal Article
Closed access
RRRithwick Rajagopal
Rithwick Rajagopal
RARajendra S. Apte
Rajendra S. Apte

28 August 2019 in Current Eye Research
Verified
Journal Article
Closed access
YBYicheng K. Bao
Yicheng K. Bao
YYYan Yan
Yan Yan
BWBradley Wilson
Bradley Wilson
MGMae O. Gordon
Mae O. Gordon
CSClay F. Semenkovich
Clay F. Semenkovich
RRRithwick Rajagopal
Rithwick Rajagopal
Purpose: In animal models, insulin resistance without severe hyperglycemia is associated with retinopathy; however, corroborating data in humans are lacking. This study aims to investigate the prevalence of retinopathy in a population without diabetes and evaluate the association of insulin resistance and retinopathy within this group. Methods: The study population included 1914 adults age ≥40 without diabetes who were assigned to the morning, fasted group in the National Health and Nutrition Examination Survey 2005–2008, conducted by the Centers for Disease Control. Retinopathy was determined using fundus photos independently graded by a reading center and insulin resistance was determined using the homeostatic model of insulin resistance. Results: Prevalence of retinopathy in those without diabetes was survey design adjusted 9.4% (174/1914). In multivariable analyses, retinopathy was associated with insulin resistance (HOMA-IR OR: 1.09, 95% CI: 1.03, 1.16; p = .0030), male gender (OR: 1.39, 95% CI: 1.04, 1.85; p = .0267), and age (OR: 1.03, 95% CI: 1.01, 1.05; p = .0203). Conclusions: Insulin resistance in the absence of overt hyperglycemia could be an early driver of retinopathy.

11 January 2018 in JCI Insight
Verified
Journal Article
Open access
PDF file
RRRithwick Rajagopal
Rithwick Rajagopal
SZSheng Zhang
Sheng Zhang
XWXiaochao Wei
Xiaochao Wei
TDTeresa Doggett
Teresa Doggett
SASangeeta Adak
Sangeeta Adak
CSClay F. Semenkovich
Clay F. Semenkovich
Membrane lipid composition is central to the highly specialized functions of neurological tissues. In the retina, abnormal lipid metabolism causes severe forms of blindness, often through poorly understood neuronal cell death. Here, we demonstrate that deleting the de novo lipogenic enzyme fatty acid synthase (FAS) from the neural retina, but not the vascular retina, results in progressive neurodegeneration and blindness with a temporal pattern resembling rodent models of retinitis pigmentosa. Blindness was not rescued by protection from light-evoked activity; by eating a diet enriched in palmitate, the product of the FAS reaction; or by treatment with the PPARα agonist fenofibrate. Vision loss was due to aberrant synaptic structure, blunted responsiveness to glial-derived neurotrophic factor and ciliary neurotrophic factor, and eventual apoptotic cell loss. This progressive neurodegeneration was associated with decreased membrane cholesterol content, as well as loss of discrete n-3 polyunsaturated fatty acid– and saturated fatty acid–containing phospholipid species within specialized membrane microdomains. Neurotrophic signaling was restored by exogenous cholesterol delivery. These findings implicate de novo lipogenesis in neurotrophin-dependent cell survival by maintaining retinal membrane configuration and lipid composition, and they suggest that ongoing lipogenesis may be required to prevent cell death in many forms of retinopathy.